Jubilant Pharmova - Demand Prospects Favourable; Execution Remains Key: Motilal Oswal
Bottles of tablets taken for random testing are displayed. (Photographer Hannelore Foerster/Bloomberg)

Jubilant Pharmova - Demand Prospects Favourable; Execution Remains Key: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Jubilant Pharmova Ltd. hosted an investor/analyst meet to discuss the business and strategic initiatives in key business segments.

With the Covid-19 disruption behind in key markets, the company expects radio pharma sales to recover in H2 FY22, supplemented by incremental sales from Ruby-Fill in Europe.

The company is proactively undertaking expansions at Montreal and Spokane to be able to cater to future demand in the contract development and manufacturing operations space.

Its novel chemical entity assets are expected to enter clinics within the next six to nine months, with subsequent planned monetisation, based on clinical outcomes.

Click on the attachment to read the full report:

Motilal Oswal Jubilant Pharmova Company Udpate.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.